Race Oncology has been given ethics approval for a Phase I trial of RC220 bisantrene alone and in combination with ... Read ...

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Researchers from Liverpool School of Tropical Medicine (LSTM) have completed a Phase I clinical trial for a new oral ...

Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream inf ...

Presented promising PK, pharmacodynamic, and safety results for Decoy20 at the American Society for Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC) annual meetings.

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.

Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected ...

Targeted chemotherapy in the abdomen using a technique called PIPAC combined with systemic standard-of-care chemotherapy is shown to be safe, with promising activity for patients with colorectal and a ...

A September 2024 article in the journal Biomedicines reviewing the findings of clinical trials for ivermectin and chloroquine ...